AI Market Mood: Stock Dashboard
AMGN
Fundamental
Technical:
Latest News:
Amgen India appoints Anumita Tripathi as Director of Corporate Affairs - IndiaMedToday neutral
AMGN
Summary: Anumita Tripathi appointed as Director of Corporate Affairs at Amgen India to manage external and internal communications
Full articleAmgen's Drug Price Suit An Issue For Legislature, Judge Told - Law360 neutral
AMGN
Summary: A Colorado nonprofit argues that Amgen's lawsuit over the state's drug price cap system is essentially a disagreement with lawmakers.
Full articleEli Lilly is a new large-cap pharma top pick at Wells Fargo - Investing.com very bullish
LLY VRTX ABBV GILD AMGN MRK BMY
Summary: Wells Fargo named Eli Lilly & Co. as its new top pick among large-cap pharmaceutical stocks, highlighting its potential for significant upside and strong pipeline.
Full articleHere's Why Eli Lilly Stock Dropped 12% Last Month - Yahoo Finance somewhat bearish
LLY NVO PFE AMGN VKTX RHHBY
Summary: Eli Lilly stock fell 20% in July after a competitor announced positive clinical trial results for an obesity drug, raising concerns about potential market share loss. The company has been a key player in the weight loss drug market, but increasing competition poses a threat to its dominance.
Full articleAmgen, Airbnb fall; Fortinet, Dynatrace rise, Wednesday, 8/7/2024 - ABC News somewhat bearish, somewhat bearish, somewhat bullish, very bullish
AMGN ABNB FTNT DT
Summary: Amgen, Airbnb stocks fall due to disappointing financial results, Fortinet, Dynatrace stocks rise on raised earnings forecast
Full articleAmgen Hit with Drug Monopoly Suit by Maryland Insurance Provider - Bloomberg Law News somewhat bearish
AMGN
Summary: Amgen Inc. is facing a proposed class action lawsuit by a Maryland health insurance provider alleging monopoly practices with blockbuster drug Enbrel.
Full articleAmgen quarterly profit slips, obesity data on track for late 2024 - Bilyonaryo somewhat bearish
AMGN
Summary: Amgen reports a 1% decrease in second-quarter profit due to higher expenses related to the development of the obesity drug MariTide, despite a 20% increase in revenue driven by the acquisition of Horizon Therapeutics. The company is focusing on progress with MariTide and plans to launch a Phase 3 program for the drug soon.
Full articleAmgen Inc. (AMGN) Q2 2024 Earnings Call Transcript | Seeking Alpha somewhat bullish
AMGN
Summary: 1. Amgen Inc. reported strong second-quarter results with 20% revenue growth across various medicines, including in-market portfolio, rare diseases, and oncology. Robust performance was driven by volume growth and positive reception of key drugs like Repatha, EVENITY, and BLINCYTO. 2. The company is confident in its long-term growth outlook, with a focus on innovation and capital allocation priorities. They have initiated activities to further expand MariTide manufacturing capacity and are committed to retiring debt by the end of 2025. 3. Forward-looking statements were made regarding the potential of MariTide in obesity, obesity-related conditions, and type 2 diabetes, with plans for a broad Phase III program, and the progress and insights gained from R&D efforts in rare diseases were highlighted.
Full articleBiopharmaceuticals Market Projected To Witness Substantial Growth, 2024-2031: Pfizer Inc ... neutral
AMGN ABBV GSK PFE NVO NVS JNJ LLY BMY RHHBY
Summary: The latest report on the Biopharmaceuticals Market provides a comprehensive analysis of the industry, including market size, trends, competitive landscape, and future growth prospects.
Full articleAMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024 | Markets Insider neutral
AMGN
Summary: Amgen (NASDAQ:AMGN) just reported results for the second quarter of 2024.
Full articleWhy Amgen (AMGN) is a Top Value Stock for the Long-Term - Yahoo News somewhat bullish
AMGN
Summary: Amgen (AMGN) is a value stock with strong fundamentals, positive earnings, and attractive valuation ratios. Value investors should consider adding AMGN to their portfolios.
Full article